ImmunityBio (NASDAQ:IBRX) Receives “Buy” Rating from D. Boral Capital

D. Boral Capital reaffirmed their buy rating on shares of ImmunityBio (NASDAQ:IBRX) in a research note published on Monday morning,Benzinga reports. The firm currently has a $30.00 price objective on the stock.

IBRX has been the topic of a number of other reports. BTIG Research assumed coverage on ImmunityBio in a report on Friday, January 10th. They set a “buy” rating and a $6.00 price target on the stock. EF Hutton Acquisition Co. I upgraded shares of ImmunityBio to a “strong-buy” rating in a research report on Wednesday, October 23rd.

ImmunityBio Price Performance

Shares of NASDAQ IBRX opened at $3.16 on Monday. The firm has a 50-day moving average of $3.39 and a 200 day moving average of $4.02. The stock has a market cap of $2.20 billion, a P/E ratio of -3.43 and a beta of 0.86. ImmunityBio has a 1 year low of $2.28 and a 1 year high of $10.53.

Institutional Trading of ImmunityBio

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in IBRX. State Street Corp increased its position in shares of ImmunityBio by 10.1% during the third quarter. State Street Corp now owns 8,654,460 shares of the company’s stock worth $32,195,000 after acquiring an additional 790,408 shares during the period. Barclays PLC lifted its holdings in shares of ImmunityBio by 127.4% during the third quarter. Barclays PLC now owns 361,036 shares of the company’s stock worth $1,344,000 after purchasing an additional 202,248 shares during the period. HighTower Advisors LLC purchased a new stake in ImmunityBio in the third quarter valued at $136,000. Mirae Asset Global Investments Co. Ltd. boosted its position in ImmunityBio by 22.0% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 25,192 shares of the company’s stock worth $99,000 after purchasing an additional 4,545 shares in the last quarter. Finally, Quantbot Technologies LP acquired a new stake in shares of ImmunityBio during the 3rd quarter valued at about $143,000. 8.58% of the stock is owned by hedge funds and other institutional investors.

About ImmunityBio

ImmunityBio, Inc, a clinical-stage biotechnology company, engages in developing therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases. Its platforms for the development of biologic product candidates include antibody-cytokine fusion proteins; DNA, RNA, and recombinant protein vaccines; and cell therapies.